E-ISSN 2602-3164
EJMI. 2022; 6(2): 147-150 | DOI: 10.14744/ejmi.2022.84390

Impact of Breast Cancer Subtypes on Pathological Complete Response Following Neoadjuvant Chemotherapy

Abdilkerim Oyman1, Melike Ozcelik1, Ibrahim Cil1, 1
1Division of Medical Oncology, Unıversity of Health Sciences, Umraniye Education and Research Hospital, Istanbul, Turkey

Objectives: We aimed to identify the clinicopathological characteristics associated with pathological complete response (pCR) following neoadjuvant chemotherapy in breast cancer. Methods: Between 2009 and 2020, 105 female patients diagnosed with non-metastatic, T1-4, N1-3 breast cancer, undergoing neoadjuvant therapy followed by surgery and then radiotherapy were included in the study. All patients received anthracycline and taxane-based treatments. Patients with Her-2 positivity received additional trastuzumab treatment. Results: A total of 105 female patients were included in the study. The median age was found to be 52 years. 50 (47.6%) patients were premenopausal and 55 (52.4%) patients were postmenopausal. Pathological complete response was obtained in 26 (24.7%) patients who received neoadjuvant therapy. In the evaluation of the factors affecting the pathological complete response, statistical significance was obtained in progesterone receptor status and breast cancer subtypes in the multivariate analysis (p<0.003, p<0.035, respectively). Conclusion: This study showed that the pCR rate was considerably higher in patients with triple negative subtype compared to those with other breast cancer subtypes. Keywords: Neoadjuvant Theraphy , pathological complete response , breast cancer

Cite This Article

Oyman A, Ozcelik M, Cil I. Impact of Breast Cancer Subtypes on Pathological Complete Response Following Neoadjuvant Chemotherapy. EJMI. 2022; 6(2): 147-150

Corresponding Author: Abdilkerim Oyman

Full Text PDF PDF Download